Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths



Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Share this!

September 20, 2017 | by Sarah Hand, M.Sc.

Biotechs like Cellectis, Juno Therapeutics and Kite Pharma have all faced patient deaths in clinical trials for their CAR-T cell immunotherapies for cancer. In an effort to address these side effects, clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

CAR-T cell immunotherapy uses engineered patient-derived or donor immune cells to help the immune system recognize and destroy cancer cells.* While the therapeutic approach has shown particular promise in treating blood-based cancers, the recent string of patient deaths has called the drugs’ safety into question.

“CAR-T cells provide an entirely new level of improved disease response among patients with certain blood cancers and hold promise for more wide-ranging use,” said Dr. Elizabeth Shpall, deputy chair and professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson. “The algorithms that we published are conservative, detailed, and will help us save lives as we move forward with these exciting but also more toxic therapies.”

In addition to research conducted by other institutions, the review paper includes data from over 100 patients treated with CAR-T therapies currently being developed to treat leukemia and lymphoma. These therapies – which target the CD19 protein present on certain cancer cells – have shown treatment response rates between 50 and 90 percent in patients who have previously been unresponsive to traditional cancer therapies.

“There have been no new treatments approved for patients with aggressive B-cell lymphomas relapsing after first line therapy in 30 years, and only about 10 percent survive long term,” said Dr. Sattva Neelapu, professor of Lymphoma and Multiple Myeloma. “Existing second-line treatments, combination chemotherapy followed by autologous stem cell transplant when possible, take three to six months – CAR T cell therapies take a few weeks.”

The review focused on prevention and treatment of two side effects of CAR-T immunotherapy: cytokine release syndrome (CRS) and CAR-T-cell-related encephalopathy syndrome (CRES). Both conditions can be fatal, highlighting the need for faster response to early symptoms of the adverse events.

The researchers provided recommendations on patient pre-treatment with chemotherapeutic agents, as well as guidelines as to how patients should be monitored during, and directly following, infusion with the CAR-T cells. Should patients begin to exhibit early symptoms of CRS or CRES, the researchers present information on how their condition can be assessed and what treatments should be administered based on the severity of the adverse event.

“We need longer term follow up of patients treated so far in clinical trials, but these are potentially curative treatments,” Neelapu said. “The toxicities are unique, and every member of the care team needs to be trained to recognize them and act accordingly.”

*Editor's Note: Wording was changed to clarify that not all CAR-T therapies use patient-derived cells.

Keywords:   CAR-T Immunotherapy, Adverse Events, Drug Safety


Share this with your colleagues!

Janssen’s iSTEP Mobile Clinical Trials Program Aims to Improve Medication Adherence

October 17, 2017 - Johnson & Johnson’s pharmaceutical division Janssen has developed a new mobile clinical trials platform to streamline clinical supply management and potentially improve patient reporting and medication adherence in these studies.

Featured In: Clinical Trials News

Antihypertensive Drugs Don’t Fully Restore Microvascular Function

October 17, 2017 - According to Researchers at Lancaster University, standard treatments for high blood pressure may not be addressing damaging circulation issues in small blood vessels.

Featured In: Pharmaceutical News

Fluorescent Dye Helps Surgeons See Cancerous Lymph Nodes

October 16, 2017 - To help identify cancerous lymph nodes, surgeons at Penn Medicine are leading a trial to see whether a fluorescent dye can be a better way to identify diseased tissue during surgery.

Featured In: Life Science News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Vendor Oversight: Five Best Practices in Optimizing Limited Resources

Treatment Allocation in Randomized Trials: Challenges and Best Practices

Daily Diabetes Management in the Virtual World

Cardiovascular Imaging for Monitoring Safety: Visualizing Outcomes

Copyright © 2016-2017 Honeycomb Worldwide Inc.